Pentoxifylline CAS 6493-05-6 Raw Materials Powder

Related Attributes

Product details

Pentoxifylline Powder Usage and Synthesis.

Pentoxifylline Powder (BL-191) is a blood rheology modifier. Pentoxifylline CAS 6493-05-6 is an orally active, non-selective phosphodiesterase (PDE) inhibitor with immunomodulatory, anti-inflammatory, hemodynamic, anti-fibrinolytic and anti-proliferative effects. Pentoxifylline CAS 6493-05-6 is an orally active, non-selective phosphodiesterase (PDE) inhibitor with immunomodulatory, anti-inflammatory, hemodynamic, anti-fibrinolytic and anti-proliferative effects.

Materials can be used to study peripheral vascular disease, cerebrovascular disease, and several other diseases involving local microcirculatory defects. Pentoxifylline Raw Materials can be used to study peripheral vascular disease, cerebrovascular disease, and several other diseases involving local microcirculatory defects.

Pentoxifylline , commonly used dosage forms include enteric-coated tablets, sustained release tablets, injections. It's a vasodilator. It can be used to improve cerebral circulation after ischemic stroke, and can be used in the treatment of peripheral vascular diseases, such as chronic obliterans with intermittent claudication.

Application/Function of Pentoxifylline Powder.

Hexaconitine Enteric Tablets/ Hexaconitine Extended Release Tablets:

It is used to improve cerebral circulation after ischemic stroke and for the treatment of peripheral vascular diseases such as chronic occlusive vasculitis with intermittent claudication.

Hexanone cacodyline injection/hexanone cacodyline for injection/hexanone cacodyline sodium chloride injection/hexanone cacodyline glucose injection:

• 1, cerebral blood circulation disorders such as temporary cerebral ischemic attack, post-stroke, cerebral ischemia-induced brain dysfunction.
• 2, peripheral blood circulation disorders such as chronic embolic vasculitis, etc.
• 3, inner ear circulation disorders such as sudden deafness, senile tinnitus and deafness.
• 4、Ocular circulation disorders such as diabetic retinal artery embolism.

Pharmacological effects of Pentoxifylline Powder

Hexaconitine Enteric Tablets / Hexaconitine Extended Release Tablets:

This product is a nonspecific peripheral vasodilator that diastens isolated canine basilar arteries. Intravenous injection increases blood volume in the canine brain, reduces cerebral vascular resistance, and promotes oxygen and glucose metabolism in the brain. It can enhance the deformability of rat red blood cells, reduce blood viscosity and increase capillary flow. Oral administration can inhibit laser-induced mesenteric artery thrombosis in rats.

Hexanone cacodylate injection:

The exact mode of action of hexoketococine and its metabolites by reducing blood viscosity and altering blood rheology and leading to improvement in clinical symptoms has yet to be determined.
Hexaconitine has a dose-dependent reduction in blood viscosity, increases the deformability of red blood cells, improves the blood rheological properties of leukocytes, and inhibits the adhesion and activation of neutrophils. In patients with chronic peripheral arterial disease, it increases blood flow, affects microcirculation and improves tissue oxygenation.

Hexaconitine for Injection:

It improves blood circulation in the brain and extremities, increases blood flow in arteries and capillaries and reduces peripheral vascular resistance, but has no effect on blood pressure.

It also improves the rheological properties of blood by improving the deformability of pathologically damaged red blood cells, inhibiting platelet aggregation, and reducing blood viscosity, thereby increasing the nutritive microcirculation in the ischemic local area. It also improves the oxidative capacity of hypoxic tissues and has a diastolic effect on bronchial tubes.

Hexanone cacodyline sodium chloride injection/hexanone cacodyline glucose injection:

Hexanone cacotheline and its metabolites improve blood rheology by reducing blood viscosity; the exact mode of action and the effect leading to improvement in clinical symptoms has yet to be determined. Hexaconitine has a dose-dependent effect on reducing blood viscosity, increasing red blood cell deformability, improving blood rheological properties of leukocytes, and inhibiting neutrophil adhesion and activation. In patients with chronic peripheral arterial vascular disease, it increases blood flow, affects microcirculation and improves tissue oxygenation.

Characterization of Pentoxifylline Powder

• (1) Enteric-coated tablets: enteric-coated tablets, appearing white after removing the coating.
• (2) Hexaconitine extended-release tablets: film-coated tablets, appearing white or off-white after removing the film coating.
• (3) Hexaconitine injection: colorless clear liquid.
• (4) Hexaconitine for injection: white or off-white loose mass or powder.
• (5) Hexaconitine sodium chloride injection: colorless clear liquid.
• (6) Hexaconitine glucose injection: colorless clear liquid.

Specification of Pentoxifylline

• (1) Hexaconitine enteric tablets: 0.1g.
• (2) Hexaconitine extended-release tablets: 0.4g.
• (3) Hexaconitine injection: 2ml: 0.1g; 5ml: 0.1g.
• (4) Hexaconitine for injection: 0.1g.
• (5) Hexaconitine sodium chloride injection: 100ml: 0.1g of hexaconitine and 0.9g of sodium chloride.
• (6) Hexanone cocaine glucose injection: 250ml: 0.1g of hexanone cocaine and 12.5g of glucose.

Why choose us?

HRK Factory

About Shipping